STK11 and large cell neuroendocrine carcinoma: used whole-exome/genome sequencing showed that LCNEC is composed of two mutually exclusive subgroups: “type I LCNECs” with bi-allelic TP53 and STK11/KEAP1 alterations (37%), and “type II LCNECs” enriched for bi-allelic inactivation of TP53 and RB1 (42%).